Lateral flow tests may fail to spot Omicron amid severe infection: Study

The study was published on the preprint website Medrxiv and has not been peer-reviewed

coronavirus testing
Photo: Bloomberg
IANS New York
2 min read Last Updated : Jan 08 2022 | 2:33 PM IST

Lateral flow tests may be less effective at detecting Omicron even when people are at their most infectious, a US real-world study has found.

According to the Daily Mail, researchers at the US Covid Sports and Society Workgroup examined lateral flow and PCR test results from 30 people working in offices where there had been an Omicron outbreak in December.

It took an average of three days longer for people to test positive on a lateral flow test, which gives results in as little as 15 minutes, after their infection had already been confirmed on a PCR test, they found.

As per the report, it is not clear whether the results simply support previous findings that PCR tests are inherently more sensitive, or if the lateral flow tests are less accurate at detecting Omicron.

Neither of the lateral flow tests brands examined -- Abbott BinaxNOW and Quidel QuickVue -- are used in the UK.

And British health chiefs have insisted the swabs dished out across the country can spot Omicron just as well as they can detect other variants.

But their US counterparts have warned that early evidence suggests they are less sensitive to the mutant strain, meaning they may incorrectly tell more people they are not infected with Omicron compared to the number of false negatives they dished out for other strains.

The study was published on the preprint website Medrxiv and has not been peer-reviewed.

--IANS

vc/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Jan 08 2022 | 2:33 PM IST

Next Story